Intercept Pharmaceuticals has pulled obeticholic acid (Ocaliva) from the U.S. market as a treatment for primary biliary ...

Intercept Pharmaceuticals has voluntarily pulled Ocaliva (obeticholic acid) from the US market following a request from the ...

Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today announced its ...

Ahead of New York Fashion Week, Gilead Sciences is strutting its marketing stuff to raise awareness of primary biliary ...

Primary sclerosing cholangitis is a rare liver complication that can develop among people with inflammatory bowel disease. Early diagnosis can help, but there’s no cure.